A 45-year-old Indian national has been sentenced to 43 months in prison for selling counterfeit cancer medications, highlighting a serious threat to vulnerable patients.
Sanjay Kumar, a 45-year-old Indian national, has been sentenced to 43 months in prison for his role in a scheme to sell counterfeit cancer medications worth tens of thousands of dollars. This fraudulent operation, which Kumar privately referred to as “just water,” came to a close last week in a Houston court, where he was also ordered to serve one year of supervised release following his prison term.
The sentencing follows Kumar’s guilty plea last year to conspiracy to traffic in counterfeit goods. This charge underscores a chilling disregard for the lives of patients battling serious illnesses.
Between August 2018 and June 2024, Kumar and his associates orchestrated the sale of what they falsely claimed was Keytruda, a vital immunotherapy drug manufactured by Merck Sharp & Dohme LLC. However, the vials sold by Kumar were dangerous imitations, lacking any active ingredients necessary for effective treatment. Keytruda is a critical medication for patients diagnosed with advanced melanoma, lung cancer, and several other aggressive cancers.
The investigation, conducted by Homeland Security Investigations and the Food and Drug Administration, revealed that the substances Kumar distributed were chemically inconsistent with the legitimate medication. Laboratory tests confirmed that the vials contained no active ingredients, rendering them completely ineffective against the diseases they were purported to treat.
Undercover federal agents ultimately apprehended Kumar after purchasing approximately $89,000 worth of the counterfeit drug. During a meeting in Houston prior to his arrest, Kumar reportedly acknowledged the risks posed by his products, admitting to agents that the counterfeit Keytruda would not treat cancer and callously comparing it to plain water.
Federal prosecutors emphasized the severity of Kumar’s actions, stating, “The defendant’s actions were not just a violation of intellectual property; they were a direct assault on the hope of vulnerable patients.”
The case was prosecuted by the Justice Department’s Computer Crime and Intellectual Property Section (CCIPS) in conjunction with the U.S. Attorney’s Office for the Southern District of Texas. Officials highlighted that this sentence serves as a warning to international traffickers who exploit the American healthcare system for fraudulent purposes.
Kumar’s conviction is part of a broader initiative by the CCIPS, which has secured over 180 convictions related to intellectual property and cybercrime since 2020. For the patients who may have unknowingly received Kumar’s counterfeit products, this sentencing marks a crucial step in addressing a case that prioritized profit over human life.
According to the Justice Department, the case underscores the ongoing efforts to combat the trafficking of counterfeit pharmaceuticals and protect patients from such dangerous schemes.